Meeting
2014 ASCO Annual Meeting
Phase I study of proteasome inhibitor bortezomib in combination with irinotecan in patients with relapsed/refractory neuroblatoma.
Authors
Rajen Mody
University of Michigan Medical Center, Ann Arbor, MI
Rajen Mody , Gregory A Yanik , Valerie Castle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT00644696
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 10051)
DOI
10.1200/jco.2014.32.15_suppl.10051
Abstract #
10051
Poster Bd #
352
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Phase I trial of chidamide, an oral HDAC inhibitor, in combination with oral etoposide in patients with refractory/recurrent neuroblastoma.
First Author: Feifei Sun
Poster
2023 ASCO Annual Meeting
A phase 1b study of crizotinib in combination with temsirolimus in pediatric ALK- or MET-aberrated relapsed or refractory neuroblastoma (ITCC-053): Results of the phase 1 part.
First Author: Kim Schellekens
Poster
2023 ASCO Annual Meeting
Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.
First Author: Brian Ko
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors.
First Author: Wang Yk